NKMax America launches SNK01-MX03 clinical trial in plaque psoriasis

Filed under: Clinical Trial News | Tags: , , , , , ,

SNK01-MX03 clinical trial : NKMax America, a US biotech company, has initiated a phase 1 trial called SNK01-MX03 to investigate its ex vivo expanded autologous natural killer cell therapeutic SNK in plaque psoriasis.

In this connection, NKMax America treated the first patient in the SNK01-MX03 clinical trial, which is a single center, dose-escalation study for SNK intravenously administered once a week for four weeks at three different dosing levels.

A total of nine patients will be enrolled in the early-stage clinical trial to probe the safety and tolerability of the autologous therapy in adults having mild to severe plaque psoriasis. The SNK01-MX03 clinical trial is being held at Angeles Hospital in Tijuana, Mexico.

SNK01-MX03 clinical trial in plaque psoriasis

NKMax America begins SNK01-MX03 clinical trial in plaque psoriasis. Photo courtesy of mwooten from Pixabay.

Commenting on the SNK01-MX03 clinical trial, Paul Song – CMO and COO of NKMax America, said: “We are looking forward to generating data that supports the safety and tolerability of SNK in patients with psoriasis.

“This trial is the starting point towards expanding our reach into autoimmune diseases.”

According to NKMax America, SNK is prepared by harvesting a small number of immune cells of the patient.  Upon completion of harvesting, NK cells are separated from the blood, purified, activated, and then expanded in a cGMP facility.

The activated NK cells, called “SNK,” are reinfused in the patient to prevent the inflammatory response associated with psoriasis.

For more clinical trial news like SNK01-MX03 clinical trial in plaque psoriasis, keep following Pharma News Daily.

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *